Quotient Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Quotient stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QTNT, but not buy additional shares or sell existing shares.
View analyst ratings for Quotient or view top-rated stocks.

Wall Street analysts have given Quotient a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Quotient wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Quotient is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Quotient.

Quotient Limited (NASDAQ:QTNT) issued its quarterly earnings data on Thursday, August, 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.02. Quotient had a negative net margin of 246.74% and a negative trailing twelve-month return on equity of 6,699.81%.
View Quotient's earnings history.

Quotient's stock was trading at $4.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, QTNT stock has decreased by 37.7% and is now trading at $2.89.
View which stocks have been most impacted by COVID-19.

1 brokerages have issued 12 month price objectives for Quotient's shares. Their forecasts range from $4.50 to $4.50. On average, they expect Quotient's share price to reach $4.50 in the next year. This suggests a possible upside of 55.7% from the stock's current price.
View analysts' price targets for Quotient or view top-rated stocks among Wall Street analysts.

Some companies that are related to Quotient include Meridian Bioscience (VIVO), Alpha Teknova (TKNO), Aspira Women's Health (AWH), OncoCyte (OCX), Lucira Health (LHDX), MyMD Pharmaceuticals (MYMD), VolitionRx (VNRX), Nymox Pharmaceutical (NYMX), Achieve Life Sciences (ACHV), ImmuCell (ICCC), Biomerica (BMRA), Trinity Biotech (TRIB), Navidea Biopharmaceuticals (NAVB), ARCA biopharma (ABIO) and Global WholeHealth Partners (GWHP).
View all of QTNT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Verastem (VSTM), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX), Novavax (NVAX), Ocular Therapeutix (OCUL) and Sorrento Therapeutics (SRNE).

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Quotient's stock is owned by a variety of institutional and retail investors. Top institutional investors include Credit Suisse AG (6.49%), BlackRock Inc. (5.56%), Highbridge Capital Management LLC (4.79%), Clearbridge Investments LLC (3.92%), Morgan Stanley (3.43%) and Morgan Stanley (3.43%). Company insiders that own Quotient stock include Edward Farrell, Jeremy Stackawitz, Perceptive Advisors Llc, Peter Buhler and Prondzynski Heino Von.
View institutional ownership trends for Quotient.

QTNT stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Highbridge Capital Management LLC, Vanguard Group Inc., TimesSquare Capital Management LLC, Castleark Management LLC, Victory Capital Management Inc., Sei Investments Co., and Los Angeles Capital Management LLC.
View insider buying and selling activity for Quotient or view top insider-selling stocks.

QTNT stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Artisan Partners Limited Partnership, Credit Suisse AG, Geode Capital Management LLC, Nuveen Asset Management LLC, Premier Asset Management LLC, and Northern Trust Corp. Company insiders that have bought Quotient stock in the last two years include Perceptive Advisors Llc, Peter Buhler, and Prondzynski Heino Von.
View insider buying and selling activity for Quotient or or view top insider-buying stocks.

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QTNT stock can currently be purchased for approximately $2.89.

Quotient has a market capitalization of $293.59 million and generates $43.38 million in revenue each year. The company earns $-108,470,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

Quotient employs 435 workers across the globe.

The official website for Quotient is www.quotientbd.com.

Quotient is headquartered at B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262.

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at (122) 716-9800 or via email at [email protected]